Home › Funds › Invesco › Invesco Health Care Fund
Fund family: Invesco · Filed by AIM INVESTMENT FUNDS (INVESCO INVESTMENT FUNDS) (CIK 826644) · SEC series S000000235
Share classes and tickers: GGHCX (C000000565), GGHYX (C000071224), GTHCX (C000000567), GTHIX (C000029647), GTHRX (C000265799)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 763 with, 19 against, 0 abstentions (not counted as with management); 2 items carried no recommendation. Shareholder proposals: 3 FOR, 18 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as Invesco’s manager page (413,145 ballot items across 270 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Invesco | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 94.3% | 718 | 94.5% | 357,245 |
| Backed environmental and social shareholder proposals at US companies | n/a | 7 | 3.1% | 5,987 |
Each ballot item this fund voted is set against the votes of the other Invesco funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most Invesco funds on 15 items (2.1% of the 714 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most Invesco funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Edwards Lifesciences Corporation | 2026-05-07 | Advisory Vote to Approve Named Executive Officer Compensation | Against | FOR — 27 of 29 Invesco funds | Against | Approved, 89.3% support |
| Medpace Holdings, Inc. | 2026-05-15 | Shareholder Stockholder proposal regarding giving shareholders an ability to call for a special shareholder meeting, if properly presented at the meeting. | Against | FOR — 13 of 13 Invesco funds | For | Failed (calculated), 34.1% support |
| Globus Medical, Inc. | 2026-06-03 | Election of two Class II directors to serve until the 2029 Annual Meeting of Stockholders: Keith W. Pfeil | Withhold | FOR — 13 of 13 Invesco funds | Against | Elected, 91.3% support |
| Quest Diagnostics Incorporated | 2026-05-20 | Shareholder Stockholder proposal regarding an independent board chairman, if properly presented at the Annual Meeting. | Against | FOR — 19 of 20 Invesco funds | For | Not approved, 25.6% support |
| Vertex Pharmaceuticals Incorporated | 2026-05-13 | Shareholder Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. | Against | FOR — 22 of 24 Invesco funds | For | Approved, 57.0% support |
| Globus Medical, Inc. | 2026-06-03 | Approval, on a non-binding, advisory basis, of the 2025 compensation of the company's named executive officers (the "Say-on-Pay" Vote). | Against | FOR — 17 of 18 Invesco funds | Against | Approved, 98.4% support |
| IDEXX Laboratories, Inc. | 2026-05-12 | Shareholder Shareholder Proposal to Give Shareholders the Ability to Call for a Special Shareholder Meeting (Proposal Six). | Against | FOR — 27 of 31 Invesco funds | For | — |
| Ligand Pharmaceuticals Incorporated | 2026-06-05 | Approval, on an advisory basis, of the compensation of the named executive officers | Against | FOR — 15 of 17 Invesco funds | Against | Approved, 94.2% support |
| AbbVie Inc. | 2026-05-08 | Shareholder Stockholder Proposal - to Adopt a Policy to Require an Independent Chair | Against | FOR — 30 of 39 Invesco funds | For | Not approved, 39.6% support |
| Mettler-Toledo International Inc. | 2026-05-07 | Advisory Vote to Approve Executive Compensation | Against | FOR — 22 of 28 Invesco funds | Against | Passed (calculated), 87.9% support |
| Medpace Holdings, Inc. | 2026-05-15 | To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement for the 2026 Annual Meeting. | Against | FOR — 17 of 21 Invesco funds | Against | — |
| Protagonist Therapeutics, Inc. | 2026-06-17 | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers. | Against | FOR — 14 of 17 Invesco funds | Against | Approved, 94.4% support |
| CVS Health Corporation | 2026-05-14 | Shareholder Stockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent. | Against | FOR — 29 of 41 Invesco funds | For | — |
| Boston Scientific Corporation | 2026-04-30 | Shareholder Stockholder proposal titled "Give Shareholders the Ability to Call for a Special Shareholder Meeting." | For | AGAINST — 21 of 32 Invesco funds | Against | Not approved, 42.8% support |
| Alnylam Pharmaceuticals, Inc. | 2026-05-20 | To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers. | Against | FOR — 17 of 29 Invesco funds | Against | — |
Download all 15 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 82.2% of this fund’s 782 such votes could be given a sector; the other 139 (17.8%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 580 | 18 | 3.1% |
| Industrials | 31 | 0 | 0.0% |
| Consumer Staples | 17 | 1 | 5.9% |
| Real Estate | 11 | 0 | 0.0% |
| Technology | 4 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 506 | 0 |
| Audit-related | 80 | 0 |
| Say-on-Pay | 71 | 0 |
| Corporate Governance | 52 | 12 |
| Compensation | 47 | 0 |
| Capital Structure | 23 | 0 |
| Other Social Issues | 5 | 4 |
| Shareholder Rights and Defenses | 4 | 0 |
| Environment or Climate | 3 | 3 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Eli Lilly and Company | May 4, 2026 | $162M | 10 | 2 |
| Johnson & Johnson | April 23, 2026 | $74M | 15 | 1 |
| AbbVie Inc. | May 8, 2026 | $73M | 8 | 1 |
| Cencora, Inc. | March 5, 2026 | $58M | 13 | 0 |
| Gilead Sciences, Inc. | April 30, 2026 | $56M | 15 | 3 |
| argenx SE | May 6, 2026 | $50M | 12 | 0 |
| argenx SE | November 18, 2025 | $50M | 1 | 0 |
| McKesson Corporation | July 30, 2025 | $39M | 14 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | Against | For |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | Against | For |
| April 23, 2026 | Johnson & Johnson | Independent Board Chair Shareholder proposal | Against | For |
| May 8, 2026 | AbbVie Inc. | Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
| April 23, 2026 | HCA Healthcare, Inc. | Stockholder proposal, if properly presented at the meeting, regarding a report on healthcare consequences. Shareholder proposal | Against | For |
| April 23, 2026 | HCA Healthcare, Inc. | Stockholder proposal, if properly presented at the meeting, regarding stockholders' right to act by written consent. Shareholder proposal | Against | For |
| June 1, 2026 | UnitedHealth Group Incorporated | If properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposal | Against | For |
| May 13, 2026 | Vertex Pharmaceuticals Incorporated | Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | Against | For |
These funds reported the same votes as Invesco Health Care Fund in the latest season, so they share this page:
791 ballot items at 78 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Invesco Health Care Fund (GGHCX) voted at 78 shareholder meetings of 77 companies, on 791 ballot items in all. Where management made a recommendation, the fund followed it on 97.6% of the items and voted against it 19 times. Its most frequent area of disagreement was corporate governance (12 of its votes against management). It voted on 21 shareholder proposals. It voted FOR the board's own proposals about as often as Invesco's funds as a whole (94.3% against 94.5%). It voted differently from most Invesco funds on 15 items.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Invesco’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.